LGD-1550

DB05785ExperimentalSmall molecule

LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

Mechanism: LGD 1550 selectively binds to all three retinoic acid receptors (RAR-alpha, RAR-beta, and RAR-gamma), resulting in alterations in the expression of genes responsible for cell differentiation and proliferation. This agent also acts as an inhibitor of activator protein 1 (AP-1), a protein that mediates trophic responses and malignant transformation.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₂₃H₃₂O₂ · 340.507 g/mol (avg)
Code names: ALRT-1550 · LGD-1550

Resolves to

Compound

Structure

InChIKeyJMPZTWDLOGTBPM-OUQSKUGOSA-NSMILESC\C(\C=C\C=C(/C)C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C)=C/C(O)=O

Targets

What you can answer from here — as of March 06, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with LGD-1550, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.